Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CLS12311 low · 1 trial · 1 indication
Number and severity of adverse events (AEs) and serious adverse events (SAEs) and worsening of disease measured by clinical (relapses) and imaging (number \& size of brain MRI lesions)
| Arm | Type | Description |
|---|---|---|
| CLS12311 low | EXPERIMENTAL | Low dose CLS12311 |
| CLS12311 medium | EXPERIMENTAL | Medium dose CLS12311 |
| CLS12311 high | EXPERIMENTAL | High dose CLS12311 |
| Name | Type | Description |
|---|---|---|
| CLS12311 low | DRUG | Peptide-coupled Red Blood Cells (RBCs) |
| CLS12311 medium | DRUG | Peptide-coupled Red Blood Cells (RBCs) |
| CLS12311 high | DRUG | Peptide-coupled Red Blood Cells (RBCs) |
| uncoupled RBCs | DRUG | autologous Red Blood Cells (RBCs) |
Inclusion Criteria: 1. RRMS according to the 2017 McDonald criteria 2. Male or female patients (assigned at birth) aged 18-55 years inclusive 3. Disease duration (since diagnosis) \<10 years 4. Expanded Disability Status Scale (EDSS) at baseline 0-5.5 5. Untreated patients or patients being off the...
CLS12311 low is an investigational small molecule being developed for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with RRMS to evaluate its safety and potential therapeutic effects.
CLS12311 low is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis is conducting clinical research on this investigational drug for the treatment of relapsing-remitting multiple sclerosis.
CLS12311 low is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied in an early-stage clinical trial to assess its safety, tolerability, and preliminary efficacy in patients with relapsing-remitting multiple sclerosis.
CLS12311 low is being evaluated in a Phase 1 clinical trial with the identifier NCT06430671, titled 'Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis.' This active, non-recruiting study has an enrollment of 11 participants and is being conducted in Czechia, Germany, Italy, and Switzerland.
CLS12311 low is a specific formulation or dosage strength of the investigational drug CLS12311. Both are being developed by Novartis AG for the treatment of relapsing-remitting multiple sclerosis. The 'low' designation indicates a lower dose or concentration of the active compound being studied in clinical trials.